Sorry, you need to enable JavaScript to visit this website.
Skip to main content
EXPERTISE

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

Orphan and rare disease CRO services

Worth Sharing?

Landscape of Rare and Orphan diseases in Asia-Pacific

There may be as many as 8,000 rare diseases, affecting between 6% and 8% of the worldwide population in total. It is estimated there are about 30 million affected people in the EU and in North America, while over 45 million people may be suffering from a rare condition in Asia, with 10 million people in China alone.

Despite the large number of known Orphan diseases, it is estimated only about 5% of rare diseases have an approved treatment.

Over the last years, we saw a major global effort in the clinical development of Orphan drugs. In fact, in 2018, the majority of new drugs approved by the FDA and EMA were Orphan medicines. Asian countries have been implementing legal frameworks similar to the Orphan Drug Act used in the US, encouraging clinical trials in many locations including South Korea, Taiwan, Singapore and The Philippines.

These new legal frameworks in Asia set forth general criteria to accelerate the registration and approvals of drugs for the treatment of rare diseases and established new rules concerning health insurance coverage, expedited registration, and marketing exclusivity periods for biopharma companies.
 
Furthermore, the Action Plan on Rare Diseases launched in late 2018 by the Asia-Pacific Economic Cooperation is expected to accelerate supportive actions to develop public actions, disease registries, and patient access to clinical trials, and to reduce enrollment durations.

Providing Orphan diseases CRO services

Rare Disease clinical studies require a full-service CRO with expertise and experience in enrolling rare disease patients. This includes expertise in site selection and access to patient registries to accelerate patient enrolment, and global regulatory knowledge regarding the specific context of Rare Disease trials and Orphan diseases trials.

About 25% of drugs granted with an Orphan designation since 2015 were concentrated on 10 major indications. For most of these indications, clinical studies involving sites from Asia-Pacific outperformed the median patient enrollment duration of rare disease trials globally.


Novotech experience in Rare and Orphan diseases


Novotech has conducted over 20 trials including these rare disease indications:

  • Acromegaly
  • Alport Syndrome
  • Alpha1antitrypsin deficiency
  • Cystic Fibrosis
  • Down Syndrome
  • Duchenne Muscular Dystrophy (DMD)
  • Fabry disease
  • Friedreich's ataxia
  • Gaucher's disease
  • Macular Telangiectasia Type 2
  • Growth Hormone Deficiency
  • Muscular Dystrophy
  • Peyronie's contracture
  • Paroxysmal nocturnal hemoglobinuria (PNH)

Sources

State of rare disease management in Southeast Asia. Shafie et al. Orphanet Journal of Rare Diseases (2016) 11:107. DOI 10.1186/s13023-016-0460
Challenges in orphan drug development and regulatory policy in China. Cheng and Xie Orphanet Journal of Rare Diseases (2017) 12:13. DOI 10.1186/s13023-017-0568-6